CRLF2 and acute lymphoblastic leukemia: The drug combinations identified in this study may represent an important weapon for this cohort since CRLF2 is altered in about 60 % of DS-ALL [26] and we showed that, at nanomolar concentrations, givinostat plus trametinib and givinostat plus venetoclax were able to kill DS-ALL CRLF2r cells, while exhibiting reduced efficacy on DS non-leukemic cells.